Recombinant human interleukin 11 (BioGeneric Pharma)

重组白细胞介素11

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRecombinant human interleukin 11 (BioGeneric Pharma)

Drug Alias NameOprelvekin生物仿制药rHuIL- 11 (BioGeneric Pharma)Oprelvekin生物类似药Oprelvekin biosimilar (BioGeneric Pharma)

ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokinesBiologics > Biosimilar

Mechanisms of ActionThrombopoiesis stimulantsInterleukin 11 receptor alpha stimulants

TargetsInterleukin 11 receptor alpha

Therapy Area/IndicationsThrombocytopenia

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusApproved

Highest Status in ChinaN/A

Originator CompaniesBiogeneic Pharma

China Registration ClassN/A

Inactive CompaniesN/A

Active IndicationsThrombocytopenia

Inactive IndicationsN/A

ATC CodeL03AC01